From: Risk-stratification in febrile infants 29 to 60 days old: a cost-effectiveness analysis
Cost ($) | Incremental Cost ($) | Effectiveness (QALY) | Incremental Effectiveness (QALY) | ICER ($/QALY) | |
---|---|---|---|---|---|
PECARN a | $3422 | – | 0.842 | – | – |
Step-by-Step | $3505 | $83 | 0.842 | −0.0002 | Dominatedb |
Boston | $3731 | $310 | 0.838 | −0.004 | Dominated |
Rochester | $3995 | $573 | 0.841 | −0.001 | Dominated |
Clinical suspicion | $4521 | $1099 | 0.837 | −0.005 | Dominated |
Philadelphia | $4774 | $1352 | 0.839 | −0.003 | Dominated |